News

Vecuronium bromide for injection is indicated for the patients with myasthenia gravis or the myasthenic (Eaton-Lambert) syndrome (muscle weakness/fatigue). The injection features Sagent’s PreventIV Measures packaging and labeling

The results from Phase 2b study suggested that lasmiditan achieved its primary endpoint of reducing a moderate or severe headache at baseline to mild or none 2 hours

The company has previously released positive results from a Phase II (DTCL100) trial evaluating KRN5500, which demonstrated reduction of pain and safety and was superior to placebo. Based

The filing includes chemistry, manufacturing and controls (CMC) section of NDA for Gattex, which is indicated for the treatment of adults suffering from short bowel syndrome (SBS). Previously,

The Trevena award includes $460,000 in direct funding, and access to millions of dollars worth of contracted research services. The NIH has awarded this contract through its Blueprint

The tie up allows the scientists of the two institutions to work together and take forward these discoveries to the next stage of research by identifying compounds that

The inspection was done by the representatives of the FDA, EMA from the Medicines and Healthcare products Regulatory Agency (MHRA) and Medical Products Agency of Sweden (MPA). As

Under an agreement signed between both the companies, Skinvisible has given Canadian marketing rights of DermSafe to Alto. Alto expects to market the product under the name DermSafePC. DermSafe

Ridaforolimus is an experimental oral mTOR inhibitor developed as a treatment for patients with metastatic soft-tissue or bone sarcomas  who had a favorable response to chemotherapy. Earlier, ARIAD and